Title:
PHARMACEUTICAL COMPOSITION FOR TREATING GROWTH HORMONE DEFICIENCY CONTAINING hGH FUSION PROTEIN
Document Type and Number:
WIPO Patent Application WO/2018/044060
Kind Code:
A1
Abstract:
The present disclosure relates to a method for administering a human growth hormone fusion protein (GX-H9) for treating growth hormone deficiency. Specifically, the present disclosure relates to a pharmaceutical composition for treating growth hormone deficiency, which comprises an hGH fusion protein (GX-H9) and a pharmaceutically acceptable carrier, wherein the fusion protein (GX-H9) is administered once a week at a dose of 0.4 to 1.6 mg per body weight kg of a pediatric patient, or administered once every two weeks at a dose of 0.8 to 3.2 mg per body weight kg of a pediatric patient. In addition, the present disclosure relates to a method for treating growth hormone deficiency, which comprising a step of administering an hGH fusion protein (GX-H9) to a patient with growth hormone deficiency once a week at a dose of 0.4 to 1.6 mg per body weight kg of the patient, or once every two weeks at a dose of 0.8 to 3.2 mg per body weight kg of the patient.
More Like This:
| WO/2009/147326 | ANALGESIC EFFECTS OF PEPTIDE TOXIN APETX2 |
| WO/2018/160722 | ANTI-RSV MONOCLONAL ANTIBODY FORMULATION |
| JP2013043850 | LIPOLYSIS PROMOTER |
Inventors:
KIM TAE KYUNG (KR)
WOO JUNG WON (KR)
LEE JOAN YOON JI (KR)
AHN YOUNG-JOO (KR)
CHA JI-EUN (KR)
RHIM HYOU YOUNG (KR)
JANG WOO ICK (KR)
WOO JUNG WON (KR)
LEE JOAN YOON JI (KR)
AHN YOUNG-JOO (KR)
CHA JI-EUN (KR)
RHIM HYOU YOUNG (KR)
JANG WOO ICK (KR)
Application Number:
PCT/KR2017/009471
Publication Date:
March 08, 2018
Filing Date:
August 30, 2017
Export Citation:
Assignee:
GENEXINE INC (KR)
HANDOK INC (KR)
HANDOK INC (KR)
International Classes:
A61K38/16; A61K38/27
Domestic Patent References:
| WO2016079302A1 | 2016-05-26 | |||
| WO2017142331A1 | 2017-08-24 |
Foreign References:
| US20100261248A1 | 2010-10-14 |
Other References:
HOYBYE, C. ET AL.: "Status of long-acting-growth hormone preparations - 2015", GROWTH HORMONE & IGF RESEARCH, vol. 25, 2015, pages 201 - 206, XP055273438
WOO, J-W. ET AL.: "A hybrid Fc-fused human growth hormone, GX-H9, shows a potential for semi-monthly administration in clinical studies", ENDOCRINE SOCIETY'S 98TH ANNUAL MEETING AND EXPO, 3 May 2016 (2016-05-03), Boston, XP055472540, Retrieved from the Internet
KIM, E-S. ET AL.: "Controlled release of human growth hormone fused with a human hybrid Fc fragment through a nanoporous polymer membrane", NANOSCALE, vol. 5, 2013, pages 4262 - 4269, XP055411456
See also references of EP 3506923A4
WOO, J-W. ET AL.: "A hybrid Fc-fused human growth hormone, GX-H9, shows a potential for semi-monthly administration in clinical studies", ENDOCRINE SOCIETY'S 98TH ANNUAL MEETING AND EXPO, 3 May 2016 (2016-05-03), Boston, XP055472540, Retrieved from the Internet
KIM, E-S. ET AL.: "Controlled release of human growth hormone fused with a human hybrid Fc fragment through a nanoporous polymer membrane", NANOSCALE, vol. 5, 2013, pages 4262 - 4269, XP055411456
See also references of EP 3506923A4
Attorney, Agent or Firm:
LEE, Cheo Young et al. (KR)
Download PDF:
Previous Patent: FITNESS MONITORING SYSTEM.
Next Patent: SYSTEM AND METHOD FOR DIAGNOSING PNEUMATIC CONTROL VALVE ONLINE
Next Patent: SYSTEM AND METHOD FOR DIAGNOSING PNEUMATIC CONTROL VALVE ONLINE